Multimarker Approach in Discriminating Patients with Symptomatic and Asymptomatic Atherosclerotic Carotid Artery Stenosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Several circulating biomarkers have been implicated in carotid atherosclerotic plaque rupture and thrombosis; however, their clinical utility remains unknown. The aim of this study was to determine the role of a large biomarker panel in the discrimination of symptomatic (S) vs. asymptomatic (A/S) subjects in a contemporary population with carotid artery stenosis (CS). Methods Prospective sampling of circulating cytokines and blood lipids was performed in 300 unselected, consecutive patients with ≥50% CS, as assessed by duplex ultrasound (age 47-83 years; 110 with A/S and 190 with S) who were referred for potential CS revascularization. Results CS severity and pharmacotherapy did not differ between the A/S and S patients. The median values of total cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) did not differ, but high-density lipoprotein (HDL) cholesterol was significantly higher (p<0.001) and triglycerides were lower (p=0.03) in the A/S-CS group than in the S-CS group. Interleukin-6(IL-6) and high-sensitivity C-reactive protein were higher (p=0.04 and p=0.07, respectively) in the S-CS group. Circulating visfatin, soluble CD 40 receptor ligand, soluble vascular cell adhesion molecule, leptin, adiponectin, IL-1β, IL-8, IL-18, monocyte chemoattractant protein-1, myeloperoxidase, matrix metalloproteinases-8, -9, and -10, and fibrinogen were similar, but tissue inhibitor of matrix metalloproteinases-1 (TIMP) was reduced in S-CS compared to A/S-CS (p=0.02). Nevertheless, incorporation of TIMP and IL-6 did not improve the HDL-cholesterol receiver operating characteristics for S-CS status prediction. S-CS status was unrelated to angiographic stenosis severity or plaque burden, as assessed by intravascular ultrasound (p=0.16 and p=0.67, respectively). Multivariate logistic regression analysis revealed low HDL-cholesterol to be the only independent predictor of CS symptoms, with an odds ratio of 1.81 (95% confidence interval=1.15-2.84, p=0.01) for HDL <1.00 mmol/L (first quartile) vs. >1.37 (third quartile). In S-CS, osteoprotegerin and lipoprotein-associated phospholipase A2 (Lp-PLA2 ) were elevated in those with recent vs. remote symptoms (p=0.01 and p=0.02, respectively). Conclusions In an all-comer CS population on contemporary pharmacotherapy, low HDLcholesterol (but not other previously implicated or several novel circulating biomarkers) is an independent predictor of S-CS status. In addition, an increase in circulating osteoprotegerin and Lp-PLA2 may transiently indicate S transformation of the carotid atherosclerotic plaque.
Abstract
Background and Purpose Several circulating biomarkers have been implicated in carotid atherosclerotic plaque rupture and thrombosis; however, their clinical utility remains unknown. The aim of this study was to determine the role of a large biomarker panel in the discrimination of symptomatic (S) vs. asymptomatic (A/S) subjects in a contemporary population with carotid artery stenosis (CS). Methods Prospective sampling of circulating cytokines and blood lipids was performed in 300 unselected, consecutive patients with ≥50% CS, as assessed by duplex ultrasound (age 47-83 years; 110 with A/S and 190 with S) who were referred for potential CS revascularization. Results CS severity and pharmacotherapy did not differ between the A/S and S patients. The median values of total cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) did not differ, but high-density lipoprotein (HDL) cholesterol was significantly higher (p<0.001) and triglycerides were lower (p=0.03) in the A/S-CS group than in the S-CS group. Interleukin-6(IL-6) and high-sensitivity C-reactive protein were higher (p=0.04 and p=0.07, respectively) in the S-CS group. Circulating visfatin, soluble CD 40 receptor ligand, soluble vascular cell adhesion molecule, leptin, adiponectin, IL-1β, IL-8, IL-18, monocyte chemoattractant protein-1, myeloperoxidase, matrix metalloproteinases-8, -9, and -10, and fibrinogen were similar, but tissue inhibitor of matrix metalloproteinases-1 (TIMP) was reduced in S-CS compared to A/S-CS (p=0.02). Nevertheless, incorporation of TIMP and IL-6 did not improve the HDL-cholesterol receiver operating characteristics for S-CS status prediction. S-CS status was unrelated to angiographic stenosis severity or plaque burden, as assessed by intravascular ultrasound (p=0.16 and p=0.67, respectively). Multivariate logistic regression analysis revealed low HDL-cholesterol to be the only independent predictor of CS symptoms, with an odds ratio of 1.81 (95% confidence interval=1.15-2.84, p=0.01) for HDL <1.00 mmol/L (first quartile) vs. >1.37 (third quartile). In S-CS, osteoprotegerin and lipoprotein-associated phospholipase A2 (Lp-PLA2 ) were elevated in those with recent vs. remote symptoms (p=0.01 and p=0.02, respectively). Conclusions In an all-comer CS population on contemporary pharmacotherapy, low HDLcholesterol (but not other previously implicated or several novel circulating biomarkers) is an independent predictor of S-CS status. In addition, an increase in circulating osteoprotegerin and Lp-PLA2 may transiently indicate S transformation of the carotid atherosclerotic plaque.
참고문헌 (48)
- Goldstein LB, "Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2011, pp.42, 517~584
- Kim JT, "Subtyping of ischemic stroke based on vascular imaging: analysis of 1,167 acute, consecutive patients", Journal of Clinical Neurology, 2, pp.225~230 (2006)
- Halliday A, "10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial", The Lancet, 376, pp.1074~1084 (2010)
- Koenig W, "Biomarkers of atherosclerotic plaque instability and rupture", Arteriosclerosis, Thrombosis, and Vascular Biology, 27, pp.15~26 (2007)
- Alvarez Garcia B, "High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque", Journal of Vascular Surgery, 38, pp.1018~1024 (2003)
- 허성혁, "Plaque Rupture is a Determinant of Vascular Events in Carotid Artery Atherosclerotic Disease: Involvement of Matrix Metalloproteinases 2 and 9", Journal of Clinical Neurology, 7(2), pp.69~76 (2011), 대한신경과학회
- Dahl TB, "Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization", Circulation, 115, pp.972~980 (2007)
- Mannheim D, "Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques", Stroke, 39, pp.1448~1455 (2008)
- Urbonaviciene G, "Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease", Atherosclerosis, 210, pp.619~624 (2010)
- Golledge J, "Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis", Stroke, 35, pp.1636~1641 (2004)
- Bornstein N, "Asymptomatic carotid artery stenosis (ACAS)", Journal of Neural Transmission, 118, pp.629~ (2011)
- Cola C, "From carotid plaque biology to serologic markers of vulnerability to predict the risk of cerebrovascular events", Acta Chirurgica Belgica, 107, pp.129~142 (2007)
- Ikonomidis I, "Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease", Atherosclerosis, 199, pp.3~11 (2008)
- Pieniazek P, "Flow reversal for proximal neuroprotection during endovascular management of critical symptomatic carotid artery stenosis coexisting with ipsilateral external carotid artery occlusion", Journal of Endovascular Therapy, 16, pp.744~751 (2009)
- Kablak-Ziembicka A, "Carotid intima-media thickness, hs-CRP and TNF-α are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease", Atherosclerosis, 214, pp.185~190 (2011)
- European Stroke Organisation, "ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)", European Heart Journal, 32, pp.2851~2906 (2011)
- Musialek P, "Safety of embolic protection device-assisted and unprotected intravascular ultrasound in evaluating carotid artery atherosclerotic lesions", Medical Science Monitor, 18, pp.MT7~MT18 (2012)
- Kwee RM, "Carotid plaques in transient ischemic attack and stroke patients: one-year follow-up study by magnetic resonance imaging", Investigative Radiology, 45, pp.803~809 (2010)
- Bassuk SS, "High-sensitivity C-reactive protein: clinical importance", Current Problems in Cardiology, 29, pp.439~493 (2004)
- Liapis CD, "ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques", European Journal of Vascular and Endovascular Surgery, 37(4 Suppl), pp.1~19 (2009)
- Koutouzis M, "Serum interleukin-6 is elevated in symptomatic carotid bifurcation disease", Acta Neurologica Scandinavica, 119, pp.119~125 (2009)
- Rudd JH, "Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron- emission tomography", computed tomography imaging study, 2009, pp.2, 107~115
- Higashikata T, "Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method", Atherosclerosis, 185, pp.165~172 (2006)
- Ste¸pien´ E, "Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects", Hypertension Research, 35, pp.531~538 (2012)
- Peeters W, "Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization", Arteriosclerosis, Thrombosis, and Vascular Biology, 29, pp.128~133 (2009)
- Sabeti S, "Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression?", Stroke, 36, pp.1400~1404 (2005)
- Montecucco F, "Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke", Stroke, 41, pp.1394~1404 (2010)
- Pelisek J, "Multiple biological predictors for vulnerable carotid lesions", Cerebrovascular Diseases, 28, pp.601~610 (2009)
- Milei J, "Atherosclerotic plaque rupture and intraplaque hemorrhage do not correlate with symptoms in carotid artery stenosis", Journal of Vascular Surgery, 38, pp.1241~1247 (2003)
- Mauriello A, "A pathobiologic link between risk factors profile and morphological markers of carotid instability", Atherosclerosis, 208, pp.572~580 (2010)
- Lombardo A, "Inflammation as a possible link between coronary and carotid plaque instability", Circulation, 109, pp.3158~3163 (2004)
- Naghavi M, "From vulnerable plaque to vulnerable patient--Part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report", American Journal of Cardiology, 98, pp.2H~15H (2006)
- Krupinski J, "Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques", Stroke, 37, pp.1200~1204 (2006)
- Turu MM, "Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound", Atherosclerosis, 187, pp.161~169 (2006)
- Hermus L, "Carotid plaque formation and serum biomarkers", Atherosclerosis, 213, pp.21~29 (2010)
- Debing E, "Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a case-control study", Vascular and Endovascular Surgery, 42, pp.122~127 (2008)
- Yamagami H, "Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients", Ultrasound in Medicine & Biology, 34, pp.1353~1359 (2008)
- Horiuchi Y, "Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels", Journal of Atherosclerosis and Thrombosis, 17, pp.722~729 (2010)
- Seo SM, "Highdensity lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention", Heart, 97, pp.1943~1950 (2011)
- Gielen S, "A new look at HDL in coronary disease: can we escape natural history?", Heart, 97, pp.1899~1901 (2011)
- Laloux P, "Lipids in ischemic stroke subtypes", Acta Neurologica Belgica, 104, pp.13~19 (2004)
- Johnsen SH, "Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromsø study", Circulation, 112, pp.498~504 (2005)
- Kim DE, "Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study", Stroke, 43, pp.1824~1830 (2012)
- Kurebayashi N, "Impact of the low- to high-density lipoprotein cholesterol ratio on composition of angiographically ambiguous left main coronary artery plaque", Circulation Journal, 75, pp.1960~1967 (2011)
- Kim DE, "Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging", Arteriosclerosis, Thrombosis, and Vascular Biology, 30, pp.449~456 (2010)
- 김정연, "High Levels of Remnant Lipoprotein Cholesterol Is a Risk Factor for Large Artery Atherosclerotic Stroke", Journal of Clinical Neurology, 7(4), pp.203~209 (2011), 대한신경과학회
- Przewłocki T, "Polyvascular extracoronary atherosclerotic disease in patients with coronary artery disease", Kardiologia Polska, 67, pp.978~984 (2009)
- 박광열, "Large-Artery Stenosis Predicts Subsequent Vascular Events in Patients with Transient Ischemic Attack", Journal of Clinical Neurology, 3(4), pp.169~174 (2007), 대한신경과학회